Stock Market Reviews

TAK (Takeda Pharmaceutical Company Limited) News

Get the latest news, insights, and market updates on TAK (Takeda Pharmaceutical Company Limited). Explore the news page 4 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players
  The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. Co
  Nov 6, 2025 - $TAK
• Accipiter Biosciences Emerges from Stealth with $12.7 Million in Seed Financing to Deliver de novo Protein Therapies for Complex Diseases
  Strong syndicate of investors co-led by Takeda and Flying Fish Partners Proceeds will advance preclinical programs in immunology and oncology Strategic partnerships established with Pfizer and Kite Pharma, a Gilead Company, to accelerate translation and expand protein design capabilities SEATTLE, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Accipiter Biosciences (“Accipiter Bio”), a biotechnology company developing de novo multifunctional biologics to treat complex diseases, today emerged from stealth with
  Nov 6, 2025 - $TAK
• Keros Therapeutics Reports Third Quarter 2025 Financial Results
  LEXINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended September 30, 2025. “We are excited that our partner Takeda
  Nov 5, 2025 - $TAK
• New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
  OSAKA, Japan & CAMBRIDGE, Mass., November 03, 2025--Takeda (TSE:4502/NYSE:TAK) announced the completion of the 7-year pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial evaluating its dengue vaccine, QDENGA®▼(Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). These data, including an exploratory analysis of a booster dose, confirm the favorable benefit and risk profile of QDENGA and that the two-dose regimen provides sustained protection against dengue. T
  Nov 3, 2025 - $TAK
• United States Multiple Myeloma Market Research Report 2025-2033, Profiles of Key Players - Novartis, Abbvie, Sanofi, Johnson and Johnson, Baxter, Pfizer, Takeda, and Bristol-Myers Squibb
  Opportunities in the U.S. multiple myeloma market include leveraging cutting-edge therapies like targeted treatments and immunotherapies, capitalizing on aging demographics, increasing disease awareness, and investing in oncology research. Expansion in combination treatments also offers significant potential. U.S. Multiple Myeloma Market U.S. Multiple Myeloma Market Dublin, Nov. 03, 2025 (GLOBE NEWSWIRE) -- The "United States Multiple Myeloma Market Size, Insights, Analysis, Growth Potential and
  Nov 3, 2025 - $TAK
• Takeda Pharmaceutical (TSE:4502) Margin Miss Reinforces Bearish Narratives After ¥250.7B One-Off Loss
  Takeda Pharmaceutical (TSE:4502) reported net profit margins of just 0.7% for the twelve months ending September 2025, down sharply from 6.4% a year earlier, as a one-off loss of ¥250.7 billion weighed heavily on results. The company’s earnings have slipped by an average of 16.1% per year over the past five years, and most recently, earnings growth remained negative. Although profit margins have come under pressure, investors are looking to the future with forecasts calling for a substantial...
  Nov 1, 2025 - $TAK
• Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year
  OSAKA, Japan, October 30, 2025--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2025 (six months ended Sep 30, 2025) and updated its full-year outlook.
  Oct 30, 2025 - $TAK
• Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading
  Asian equities traded in the US as American depositary receipts were headed lower Thursday morning,
  Oct 30, 2025 - $TAK
• Competitive Landscape of Obesity Therapeutics Market Enters High-Growth Phase, Fueled by GLP-1 Surge and Expanding Oral Treatments | DataM Intelligence
  According to DataM Intelligence, the obesity therapeutics market is on the cusp of major expansion. Although precise market size figures for this report were not publicly disclosed in full, broader indicators show the weight-loss/obesity therapeutics subset rising from US$ 3.30 billion in 2023 to US$ 3.92 billion in 2024, and projected to approach US$ 20.84 billion by 2033 at a CAGR of approximately 20.6%. This trajectory reflects the dramatic increase in demand for pharmacological treatments of
  Oct 30, 2025 - $TAK
• HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation
  CAMBRIDGE, Mass., October 27, 2025--Takeda announced the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S.
  Oct 27, 2025 - $TAK